SynthesisInternational journal of molecular sciences2026
Beta-Blocker Therapy After Myocardial Infarction: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.
Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical benefit of beta-blocker treatment in patients with a previous myocardial infarction (MI) and without a reduced left ventricular ejection fraction (LVEF) is not established. This study aims at assessing the impact of beta-blocker treatment after an MI based on the type of MI at presentation, the LVEF, and the patient's sex in the setting of contemporary management of MI. We searched the PubMed and Cochrane Library databases for randomized clinical trials published over last ten years that reported beta-blockers' impact on prognosis in patients with LVEF > 40%. A meta-analysis was performed to assess the association between the beta-blocker treatment and outcomes in different patient subgroups based on the type at presentation (with ST segment elevation, STEMI, or without ST segment elevation, NSTEMI), LVEF, and sex. In the overall analysis, the association between beta-blocker non-use and the composite endpoint was not statistically significant under the random-effects model. In subgroup analyses, a higher risk with beta-blocker non-use was suggested in NSTEMI and in patients with mildly reduced LVEF in common-effect estimates (NSTEMI: RR 1.13, 95% CI 1.02-1.25; I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.